SCHEMBL7790207

SCHEMBL7790207

O=[PH](O)C(CNC1CCCCCC1)P(=O)(O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 5/20 0.58
ERAP2 Q6P179 5/20 0.58
KDM4E B2RXH2 2/20 0.47
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MMP2 P08253 4/20 0.37
CA12 O43570 3/20 0.37
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA9 Q16790 3/20 0.37
MMP1 P03956 2/20 0.37
MMP8 P22894 1/20 0.37
MMP3 P08254 1/20 0.37
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
SCN1A P35498 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN3A Q9NY46 1/20 0.35
FDPS P14324 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9315989 0.77 ANPEP (0.68) ANPEPERAP2KDM4EHTTSMN1; SMN2
SCHEMBL9564518 0.77 ANPEP (0.68) ANPEPERAP2KDM4EHTTSMN1; SMN2
SCHEMBL9316055 0.77 ANPEP (0.68) ANPEPERAP2KDM4EHTTSMN1; SMN2
SCHEMBL16111997 0.72 ANPEP (0.60) ANPEPERAP2KDM4ESMN1; SMN2MMP2
SCHEMBL9746636 0.72 ANPEP (0.60) ANPEPERAP2KDM4ESMN1; SMN2MMP2
SCHEMBL8713138 0.70 ANPEP (0.58) ANPEPERAP2KDM4EHTTSMN1; SMN2
SCHEMBL27980382 0.65 KDM4E (1.00) ANPEPERAP2KDM4EHTTSMN1; SMN2
SCHEMBL3393821 0.65 KDM4E (0.74) ANPEPERAP2KDM4EHTTSMN1; SMN2
SCHEMBL30777623 0.64 KDM4E (0.71) ANPEPERAP2KDM4EHTTSMN1; SMN2
Medronic Acid SCHEMBL12493737 0.63 ANPEP (0.46) ANPEPERAP2KDM4ESMN1; SMN2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6329354-B1 ADMINISTERING BONE ACTIVE PHOSPHONATE, ADMINISTERING ESTROGEN HORMONE THE PROCTER & GAMBLE COMPANY 2001-12-11 US disclosed
EP-1158987-A1 METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2001-12-05 EP disclosed
WO-2000051617-A1 METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2000-09-08 WO disclosed
US-5869471-A Methods for the treatment of arthritis using phosphonates and NSAIDS THE PROCTOR & GAMBLE COMPANY (US) 1999-02-09 US disclosed
EP-0779813-A4 PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS PROCTER & GAMBLE (US) 1998-05-06 EP disclosed
EP-0779812-A4 METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE PROCTER & GAMBLE (US) 1997-09-10 EP disclosed
EP-0779812-A1 METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE THE PROCTER & GAMBLE COMPANY (US) 1997-06-25 EP disclosed
EP-0779813-A1 PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS THE PROCTER & GAMBLE COMPANY (US) 1997-06-25 EP disclosed
US-5616560-A Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone THE PROCTER & GAMBLE COMPANY (US) 1997-04-01 US disclosed
WO-1996007418-A1 PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS THE PROCTER & GAMBLE COMPANY (US) 1996-03-14 WO disclosed
WO-1996007417-A1 METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE THE PROCTER & GAMBLE COMPANY (US) 1996-03-14 WO disclosed
EP-0650361-A1 COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1995-05-03 EP disclosed
EP-0573604-B1 METHODS FOR THE TREATMENT OF OSTEOPOROSIS PROCTER & GAMBLE PHARMA (US) 1995-03-15 EP disclosed
WO-1994000130-A1 COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1994-01-06 WO disclosed
EP-0573604-A1 METHODS FOR THE TREATMENT OF OSTEOPOROSIS. NORWICH EATON PHARMA (US) 1993-12-15 EP disclosed
WO-1992014474-A1 METHODS FOR THE TREATMENT OF OSTEOPOROSIS NORWICH EATON PHARMACEUTICALS, INC. (US) 1992-09-03 WO disclosed